NCIt definition : A bispecific antibody directed against the human negative immunoregulatory checkpoint
receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated
antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic
activities. Upon administration, danvilostomig targets and binds to both PD-1 and
CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1-
and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores
immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune
response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs
in the tumor microenvironment (TME) and negatively regulate the activation and effector
functions of T-cells. They play key roles in the downregulation of the immune system
and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with
SI-B003 may enhance T-cell activation and proliferation more than the blockade of
either immune checkpoint receptor alone.;
UNII : B4Q67YX49Q;
CAS number : 2599198-80-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2599198-80-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)